← Back to headlines
Bristol-Myers Squibb Divests Cellares Amid Breyanzi Strategy Shift
The pharmaceutical giant announced its exit from the Cellares division, prompting investor scrutiny over how the move will impact the commercial trajectory of its key multiple myeloma treatment, Breyanzi.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
South Korean Retail Investors Shift Billions to US Stocks Amid ETF Curbs
24m ago
HDFC Bank CEO Sashidhar Jagdishan to Step Down in October
3h ago
FSSAI Bans Everest and Laljee Godhoo From Selling Substandard Hing Powder
4h ago
UAE Central Bank Launches Probe Into Banque Misr Over US Money Laundering Warnings
4h ago